Edinburgh Innovations (EI), the University’s commercialisation service, has helped an Edinburgh-led collaboration with FUJIFILM Diosynth Biotechnologies UK (FDB) to secure Prosperity Partnership funding this month to develop more cost-effective ways to make modern antibody-based medicines.
The collaboration was awarded funding from the Engineering and Physical Sciences Research Council (EPSRC) and the Biotechnology and Biological Sciences Research Council (BBSRC), both of which are part of UK Research and Innovation (UKRI). Including industry funding, the total project value is £8.7 million.
Susan Rosser, Professor of Synthetic Biology, will lead a three-university research team working with FDB. The collaboration was one of nine business-led research partnerships in the UK awarded Prosperity Partnership funding.
Dr George Baxter, CEO of Edinburgh Innovations, said: “This major funding award shows the leading position of Edinburgh and our partners Manchester and York as successful collaborators with businesses and other organisations.
“Only by working together can academic researchers and commercial businesses both maximise the impact of their work, for mutual benefit and common goals.”
The EI team offers support to any member of staff looking to commercialise their research and encourages colleagues to get in touch with any questions they might have about the process.
Find out more on the EI website.